

KERYX BIOPHARMACEUTICALS INC  
Form 8-K  
October 19, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): October 14, 2015**

**Keryx Biopharmaceuticals, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**000-30929**  
**(Commission**

**File Number)**  
**750 Lexington Avenue**

**13-4087132**  
**(IRS Employer**

**Identification No.)**

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

**New York, New York 10022**

**(Address of Principal Executive Offices)**

**(212) 531-5965**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act.
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- .. Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

**Item 1.01 Entry into a Material Definitive Agreement.**

The information set forth in Item 3.02 of this Current Report on Form 8-K is incorporated into this Item 1.01 by reference.

**Item 3.02 Unregistered Sales of Equity Securities.**

*Closing of Private Placement*

On October 15, 2015, Keryx Biopharmaceuticals, Inc. ( Keryx or the Company ) completed the sale of \$125 million of Convertible Senior Notes due 2020 (the Notes ), in a private placement (the Private Placement ) to funds managed by The Baupost Group, L.L.C (the Investor ).

*Notes Purchase Agreement and Indenture*

The Company sold the Notes pursuant to a Notes Purchase Agreement dated October 14, 2015 (the Notes Purchase Agreement ) between the Company and the Investor. The Notes were issued under an Indenture dated as of October 15, 2015, with The Bank of New York Mellon Trust Company, N.A. as trustee (the Indenture ). Under the terms of the Indenture, the Notes may be converted into shares of Company common stock at the discretion of the Investor (with a conversion price that is subject to adjustment based on the occurrence of certain events). In furtherance thereof, the Company will seek stockholder approval to ensure that it has an adequate share reserve to cover any conversions by Investor, and if any necessary share increases are not approved, the Company will pay a portion of the conversion amount in cash. Further, the Indenture subjects the Company to certain financial and business covenants. Copies of the Notes Purchase Agreement and Indenture are attached as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K, respectively, and are incorporated herein by reference. The foregoing summary of the Indenture does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement.

*Registration Rights Agreement*

In connection with the Private Placement, Keryx entered into a Registration Rights Agreement with the purchasers of the Notes (the Registration Rights Agreement ), pursuant to which Keryx agreed to (i) file a registration statement (the Resale Registration Statement ) with the Securities and Exchange Commission (the SEC ) covering the resale of the Notes and the underlying common stock which the Notes are convertible into upon the written request of the Investor, and (ii) use commercially reasonable efforts, subject to receipt of necessary information from all the purchasers of the Notes, to cause the SEC to declare the Resale Registration Statement effective. Further, the Registration Rights Agreement permits the Investor to demand from time to time that the Company file a shelf Registration Statement pursuant to Rule 415 of the Securities Act from which any number of shelf takedowns may be conducted upon written request from the Investor. Finally, the Registration Rights Agreement affords the Investor certain piggyback registration rights.

The foregoing summary of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement. A copy of the Registration Rights Agreement is attached as Exhibit 10.3 to this Current Report on Form 8-K and is incorporated herein by reference.

The Notes were offered and sold in a private placement to certain eligible investors pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the Securities Act ). The Notes have not been registered under the Securities Act, or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration under or an applicable exemption from such registration requirements. This Current Report on Form 8-K does not constitute an offer to sell, or a solicitation of an offer to purchase, the Notes in any jurisdiction in which such offer or solicitation would be unlawful.

**Item 8.01 Other Events.**

In connection with the Private Placement, on October 15, 2015, Keryx issued a press release announcing the closing of the Private Placement. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibits are filed as part of this report:

<b>Exhibit Number</b>	<b>Description</b>
10.1	Notes Purchase Agreement, dated as of October 14, 2015, between Keryx Biopharmaceuticals, Inc. and Baupost Group Securities, L.L.C.
10.2	Indenture, dated as of October 15, 2015, between Keryx Biopharmaceuticals, Inc. and The Bank of New York Mellon Trust Company, N.A.
10.3	Registration Rights Agreement, dated as of October 15, 2015, between Keryx Biopharmaceuticals, Inc. and Baupost Group Securities, L.L.C.
99.1	Press release issued by Keryx Biopharmaceuticals, Inc., dated October 15, 2015.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Keryx Biopharmaceuticals, Inc.**  
(Registrant)

Date: October 19, 2015

By: /s/ Brian Adams  
Brian Adams  
Corporate Secretary

- 4 -

**INDEX TO EXHIBITS**

<b>Exhibit Number</b>	<b><u>Description</u></b>
10.1	Notes Purchase Agreement, dated as of October 14, 2015, between Keryx Biopharmaceuticals, Inc. and Baupost Group Securities, L.L.C.
10.2	Indenture, dated as of October 15, 2015, between Keryx Biopharmaceuticals, Inc. and The Bank of New York Mellon Trust Company, N.A.
10.3	Registration Rights Agreement, dated as of October 15, 2015, between Keryx Biopharmaceuticals, Inc. and Baupost Group Securities, L.L.C
99.1	Press release issued by Keryx Biopharmaceuticals, Inc., dated October 15, 2015.